AR103728A1 - Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2 - Google Patents

Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2

Info

Publication number
AR103728A1
AR103728A1 ARP160100435A ARP160100435A AR103728A1 AR 103728 A1 AR103728 A1 AR 103728A1 AR P160100435 A ARP160100435 A AR P160100435A AR P160100435 A ARP160100435 A AR P160100435A AR 103728 A1 AR103728 A1 AR 103728A1
Authority
AR
Argentina
Prior art keywords
inhibitors
dimetoxifenilos
monoamine transporter
vesicular monoamine
deuterium
Prior art date
Application number
ARP160100435A
Other languages
English (en)
Inventor
Zhang Chengzhi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR103728A1 publication Critical patent/AR103728A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Dimetoxifenilos como inhibidores del VMAT2, composiciones farmacéuticas con los mismos y sus métodos de uso. Reivindicación 1: Un compuesto caracterizado por la fórmula estructural (1) o una sal del mismo, en donde: R¹ - R² y R²¹ se seleccionan de manera independiente del grupo que consiste en -CH₃, -CH₂D; -CD₂H y -CD₃; R³ - R²⁰ se seleccionan de manera independiente del grupo que consiste en hidrógeno y deuterio; y por lo menos uno de R¹ - R²¹ es deuterio o contiene deuterio.
ARP160100435A 2015-02-18 2016-02-18 Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2 AR103728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562117654P 2015-02-18 2015-02-18

Publications (1)

Publication Number Publication Date
AR103728A1 true AR103728A1 (es) 2017-05-31

Family

ID=56692737

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100435A AR103728A1 (es) 2015-02-18 2016-02-18 Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2

Country Status (12)

Country Link
US (1) US10722479B2 (es)
EP (1) EP3258926A4 (es)
JP (1) JP2018507210A (es)
AR (1) AR103728A1 (es)
BR (1) BR112017017673A2 (es)
CA (1) CA2976229A1 (es)
EA (1) EA201791839A1 (es)
IL (1) IL253901A0 (es)
MA (1) MA41557A (es)
MX (1) MX2017010567A (es)
TW (1) TW201630871A (es)
WO (1) WO2016133989A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
EP4153564A4 (en) 2020-05-19 2024-06-19 Cybin IRL Limited DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852843B (en) 1984-05-15 1985-11-27 Warner Lambert Co Bevantolol preparation
BRPI0711221A2 (pt) * 2006-05-26 2012-03-13 Auspex Pharmaceuticals, Inc Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
BRPI0913457B8 (pt) * 2008-09-18 2021-08-31 Auspex Pharmaceutical Inc Composto e composição farmacêutica
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
BR112015005894B1 (pt) * 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
JP6476174B2 (ja) * 2013-06-19 2019-02-27 ソム イノヴェーション バイオテック、ソシエダッド リミターダ 運動過剰障害の予防および／または治療における使用のための治療剤

Also Published As

Publication number Publication date
EP3258926A1 (en) 2017-12-27
IL253901A0 (en) 2017-10-31
WO2016133989A1 (en) 2016-08-25
MA41557A (fr) 2017-12-26
JP2018507210A (ja) 2018-03-15
TW201630871A (zh) 2016-09-01
MX2017010567A (es) 2018-03-16
EP3258926A4 (en) 2018-11-14
US10722479B2 (en) 2020-07-28
US20180036260A1 (en) 2018-02-08
CA2976229A1 (en) 2016-08-25
EA201791839A1 (ru) 2018-02-28
BR112017017673A2 (pt) 2018-07-17

Similar Documents

Publication Publication Date Title
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
CR20170571A (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmaceúticas que los contienen.
AR103355A1 (es) Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
BR112017006240A2 (pt) novos compostos
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CO2018003367A2 (es) Benzamidas sustituidas con isoxazolina y análogos como insecticidas
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
AR103728A1 (es) Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2
AR103316A1 (es) Inhibidores de dihidroquinazolina de terminasa viral
AR106958A1 (es) Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne
AR103354A1 (es) INHIBIDORES DE 3-FLUORO-BENZONITRILO DE 11-b-HIDROXILASA

Legal Events

Date Code Title Description
FB Suspension of granting procedure